- CA$11.06m
- CA$4.72m
- CA$21.91m
- 41
- 75
- 59
- 60
Annual income statement for Medicure, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 11.6 | 21.7 | 23.1 | 21.7 | 21.9 |
| Cost of Revenue | |||||
| Gross Profit | 5.13 | 12.7 | 16.1 | 14 | 13.1 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 19.7 | 23.8 | 21.9 | 22.5 | 24.6 |
| Operating Profit | -8.11 | -2.09 | 1.19 | -0.854 | -2.74 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -6.84 | -0.759 | 1.39 | -0.897 | -0.783 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -6.84 | -0.727 | 1.36 | -0.922 | -1.04 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -6.84 | -0.727 | 1.36 | -0.922 | -1.04 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -6.84 | -0.727 | 1.36 | -0.922 | -1.04 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.721 | -0.104 | 0.131 | -0.088 | -0.1 |